

1 Dalmore Drive,
Scoresby,
Victoria 3179
AUSTRALIA
T: +61 (0)3 9763-1287
F: +61 (0)3 9763-2817
www.generabiosystems.com

Monday, 4 March 2019

**ASX Announcement – GENERA BIOSYSTEMS LIMITED (ASX: GBI)
EXTENSION OF ENTITLEMENT OFFER CLOSING DATE**

Genera Biosystems Limited (ASX:GBI) advises that the Closing Date for the present Non-Renounceable Entitlement Offer will be extended by one further week, to 5.00pm (AEDT) 15 March 2019.

The reason for the additional extension is that the CEO has only just returned from overseas which impacted the timing for the lodgment of the Company's Half Year Report. The Company anticipates that the Half Year Report will be lodged with ASX late this week. The extended closing date of 15 March should provide shareholders sufficient time to consider the contents of the report.

As announced on 31 January 2019, the Company is undertaking a non-renounceable Entitlement Issue of four (4) Shares for every five (5) Shares, at an issue price of \$0.13 (13 cents) per share to raise approximately \$11.45 million (**Entitlement Offer**).

An updated indicative timetable in relation to the Entitlement Offer is provided below:

Key indicative dates*

Offer opens	11 February 2019
Closing Date	15 March 2019
Securities quoted on a deferred settlement basis	18 March 2019
ASX notified of under subscriptions	20 March 2019
Issue date	22 March 2019

**The above timetable is indicative only and subject to change. Subject to the ASX Listing Rules, the directors of the Company reserve the right to vary these dates, including the Closing Date, without notice. The directors may extend the period of the Entitlement Offer or bring forward the Closing Date at their discretion.*

The Prospectus for the Entitlement Offer has been mailed to Eligible Shareholders and is available on both the Company and ASX's website. Eligible Shareholder should read the Prospectus and will need to complete the personalised Entitlement and Acceptance Form which accompanies the Prospectus to apply for New Shares and Shortfall Shares.

For further information please contact:

Mr Richard Hannebery
Chief Executive Officer
Genera Biosystems Limited
Telephone: +61 (0)3 9763 1287
www.generabiosystems.com.au

About Genera Biosystems : Genera Biosystems Limited (“GBI”) is an Australian Securities Exchange listed molecular diagnostics company, which develops, manufactures and distributes advanced PCR molecular diagnostics tests.

Genera’s single-well high multiplex AmpaSand® testing platform can detect up to 125 target analytes in a single-well of a reaction plate. Unlike traditional real-time PCR approaches, AmpaSand® single-well multiplex tests when run on a seamlessly integrated flow cytometry and liquid handling system can provide unparalleled throughput capability and cost efficiency for high volume pathology laboratories qualitative molecular testing needs.¹

Genera manufactures products in its Australian Therapeutics Goods Administration certified manufacturing facility in Scoresby, Victoria, Australia.

PapType®, an ARTG listed and CE-marked MDx test, simultaneously detects and identifies 14 high-risk types of HPV and 2 low risk HPV types in a single-well. These high-risk HPV types are responsible for 99.7% of all cases of cervical cancer.

In addition to PapType®, Genera has also commercialized and gained ARTG listing and CE mark for RTIplex™, a single-well multiplex MDx that identifies 15 common upper respiratory tract pathogens, including Influenza A & B, as well as 10 other viral and 3 bacterial disease-causing microbial targets.

Genera’s development pipeline includes a new 8-plex sexually transmitted infections panel that is expected to be available in the 1st half of 2019, with plans to broaden the AmpaSand® test menu further to 6 highly competitive single-well multiplex MDx assays by 2019.

PapType®, RTIplex™, and the tests in development, employ the AmpaSand® biochemistry as well as Genera’s proprietary ARTG listed and CE-IVD marked QPlots™ automated analytical and reporting software that is compatible with most Laboratory Information Management Systems (‘LIMS’) .

All the components of the Genera MDx system, including AmpaSand® and QPlots™, have been optimized to run on Beckman Coulter’s innovative CytoFLEX™ flow cytometry system.

¹ All ‘plate based’ Real Time PCR platforms can ‘multiplex’ up to 4 targets per well assuming 4 available channels of a Real Time PCR instrument. To multiplex greater than 4 target analytes in a test most platforms require use of additional wells of a plate to test for the additional target analytes. As such commercially, their multiplexing capability is restricted due to a direct trade-off with volume throughput per plate (96 or 384 well). Genera’s AmpaSand® technology facilitates the multiplexing of up to ~125 target analytes **in a single-well** of a plate. On a like for like basis depending on the number of target analytes detected in a multiplex assay Genera’s AmpaSand® technology facilitates > 4X relative volume throughput. High volume throughput is a key commercial consideration for all large pathology labs undertaking HPV and STI testing.